Base and Prime Editing Market Outlook 2026–2038: Market Size, Growth Drivers, Key Players, Strategic Developments & Adoption Forecast for In Vivo Base Editing, Prime Editing and CRISPR Nuclease Therapies in Rare Liver Disease, Cardiovascular Disease and Individualized Platform Therapies — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines how in vivo gene editing — base editors that change a single DNA letter, prime editors that rewrite short sequences and CRISPR nucleases that switch genes off, all delivered by infusion in lipid nanoparticles rather than by taking cells out of the body — will move from rare liver diseases into cardiovascular and other common conditions over the next twelve years. The evidence base has shifted in two years. Beam Therapeutics' BEAM-302 corrected the alpha-1 antitrypsin mutation in 29 treated patients, with 94% corrected protein and an 84% reduction in the mutant protein at the 60 mg dose and no serious adverse events, and a pivotal cohort under an accelerated-approval design starts in the second half of 2026. CRISPR Therapeutics' CTX310 cut ANGPTL3 by 79%, triglycerides by 48% and LDL cholesterol by 53% with a single dose, sustained through a year and published in the New England Journal of Medicine in August 2026. Eli Lilly bought Verve Therapeutics and its PCSK9 base editor, which lowered LDL by 59% at the top dose, in June 2025. Intellia intends to file lonvo-z for hereditary angioedema in the second half of 2026, while a severe liver event paused its phase 3 cardiomyopathy programme in October 2025. And the FDA's plausible mechanism pathway, announced in November 2025 after the bespoke base editor that saved an infant with CPS1 deficiency, with draft guidance in February 2026, opens a route for individualized editing therapies. The brief maps the technology, its indicative market size and forecast, the factors behind its growth, the developments of the last 24 months, the key players operating in the space and the adoption trajectory to 2038.

It is a focused 110-page decision brief for pharmaceutical and biotechnology companies, lipid nanoparticle and manufacturing providers, cardiology, hepatology and rare disease centres, payers, regulators and investors. It presents an indicative trajectory rather than a segmented market model. Its purpose is to identify which editing modalities and indications reach approval first, how safety, delivery and regulation change the pace from rare to common disease, and who captures the resulting value.

In vivo gene editing changes DNA inside the body with a single infusion. A lipid nanoparticle carries mRNA for the editor and a guide RNA to the liver, where hepatocytes take it up, make the editor for a few days and carry the resulting DNA change permanently. CRISPR nucleases cut DNA to switch a gene off — Intellia's lonvo-z knocks out kallikrein for hereditary angioedema and nex-z knocks out transthyretin for amyloidosis; CRISPR Therapeutics' CTX310 knocks out ANGPTL3 to lower triglycerides and LDL. Base editors change one DNA letter without cutting both strands — Beam's BEAM-302 converts the alpha-1 antitrypsin Z mutation back to the healthy sequence, and Verve's PCSK9 editor, now Lilly's, switches off a cholesterol gene. Prime editors rewrite short sequences and can in principle correct most small mutations; Prime Medicine has shown first efficacy in chronic granulomatous disease and is moving to alpha-1 antitrypsin deficiency.

The data now reach pivotal quality. BEAM-302 corrected the mutation in 29 patients followed up to 18 months: at the 60 mg dose, total alpha-1 antitrypsin reached 16.1 µM, 94% of it the corrected protein, with the mutant protein cut 84% and every patient above the 11 µM protective threshold, with no serious adverse events and the pivotal cohort of about 50 patients starting in the second half of 2026 under an accelerated-approval design built on biomarkers. CTX310 cut ANGPTL3 by 79%, triglycerides by 48% and LDL by 53% at the top dose in 15 patients with refractory dyslipidaemia, sustained through a year with no treatment-related serious adverse events. Verve's PCSK9 editor cut LDL by 59% at the top dose in 14 participants before Lilly acquired the company. Intellia has dosed more than 450 patients with nex-z in phase 3 and completed enrolment for lonvo-z, with a filing planned for the second half of 2026 — and in October 2025 a severe liver-enzyme and bilirubin event paused nex-z dosing pending risk mitigation. The bespoke base editor for an infant with CPS1 deficiency was designed, approved and delivered in six months and reported in May 2025.

The constraints are safety, delivery beyond the liver, durability of evidence and regulation. Liver enzyme elevations recur across programmes and the nex-z event shows a one-time, irreversible therapy will be judged on rare severe events; off-target edits and long-term follow-up remain open; lipid nanoparticles reach the liver well and other tissues poorly; and for common conditions such as high cholesterol, a permanent edit competes with injectable antibodies and small interfering RNAs that can be stopped. Regulation is moving faster than the science expected: the FDA plausible mechanism pathway allows individualized therapies to be approved on mechanism, target engagement and consecutive patient benefit, with platform data supporting related products. The decade's question is whether cardiovascular editing earns outcome data and a safety record good enough to be given to otherwise healthy people.

The in vivo gene editing market — base, prime and nuclease editing development spending, acquisition and partnership value recognised, LNP and editor manufacturing and clinical supply in 2026, and product sales thereafter — is estimated at USD 0.6–0.9 billion in 2026, led by pivotal and phase 3 programmes at Intellia, Beam, CRISPR Therapeutics and Lilly, LNP and editor manufacturing and partnership value. Meticulous Next™ expects it to reach USD 14–20 billion by 2038, an indicative CAGR of 30–33%. Growth is driven by the first approvals in hereditary angioedema and alpha-1 antitrypsin deficiency around 2027 to 2029, by transthyretin amyloidosis and other rare liver diseases, by individualized therapies under the plausible mechanism pathway, and from the early 2030s by cardiovascular editing of PCSK9, ANGPTL3 and lipoprotein(a) in refractory and high-risk patients. The forecast is sensitive to safety events in phase 3 and to whether cardiovascular outcome trials succeed. The United States leads on programmes, approvals and the individualized pathway; Europe and the United Kingdom contribute trials and conditional pathways; China advances in vivo editors through YolTech, Correctseq, AccurEdit and HuidaGene; rare liver disease centres carry the first indications and cardiology the second.

The base case assumes lonvo-z approval in 2027, BEAM-302 approval around 2029, nex-z resumption and approval by 2030 and first cardiovascular approval in refractory populations around 2032. An accelerated case assumes clean phase 3 safety and early cardiovascular outcome signals, bringing the inflection to 2030 and lifting the 2038 value to the top of the range. A delayed case assumes further severe liver events, long-term off-target concerns or failed cardiovascular outcome trials, pushing the inflection to 2034 and confining the market to rare disease.

Growth drivers

•      One-time cures for rare liver diseases with lifelong treatment burden: hereditary angioedema, alpha-1 antitrypsin deficiency, transthyretin amyloidosis.

•      Pivotal-quality data: BEAM-302's 94% corrected protein in 29 patients and CTX310's 53% LDL reduction sustained a year.

•      Regulatory acceleration: accelerated approval on biomarkers for BEAM-302 and the FDA plausible mechanism pathway for individualized therapies.

•      Pharma commitment: Lilly's acquisition of Verve and the ACC's 2026 scientific statement on cardiovascular gene editing.

Enablers

•      Lipid nanoparticle delivery to the liver proven across nuclease, base and prime editors.

•      Editor engineering that avoids double-strand breaks and reduces off-target activity.

•      Manufacturing of editor mRNA, guide RNA and LNPs from the mRNA vaccine supply chain.

•      Long-term follow-up frameworks and registries from ex vivo editing and gene therapy.

Restraints and barriers

•      Severe liver events, as in nex-z phase 3, and the irreversibility of a one-time edit.

•      Off-target editing and the absence of decades-long safety data.

•      Delivery limited to the liver with current LNPs.

Competition in common disease from reversible antibodies, siRNAs and oral drugs.

Five converging forces will determine how fast, and how far, in vivo editing moves from rare to common disease: (1) phase 3 safety and the first approvals; (2) regulatory pathways including accelerated approval and the plausible mechanism route; (3) cardiovascular outcome evidence; (4) delivery beyond the liver; and (5) pharma investment and pricing of one-time therapies. The brief assesses each force for direction, speed and confidence.

The key players operating in in vivo gene editing include Intellia Therapeutics, Inc., Beam Therapeutics Inc., CRISPR Therapeutics AG, Eli Lilly and Company (Verve Therapeutics), Prime Medicine, Inc., Regeneron Pharmaceuticals, Inc., Vertex Pharmaceuticals Incorporated, Novartis AG, Pfizer Inc., AstraZeneca PLC, Arbor Biotechnologies, Inc., Scribe Therapeutics Inc., Tune Therapeutics, Inc., nChroma Bio, Inc., Epicrispr Biotechnologies, Inc., Metagenomi, Inc., Tessera Therapeutics, Inc., Mammoth Biosciences, Inc., YolTech Therapeutics Co., Ltd., Correctseq Therapeutics Co., Ltd., AccurEdit Therapeutics, HuidaGene Therapeutics Co., Ltd., Acuitas Therapeutics, Inc., Genevant Sciences Corporation, Arcturus Therapeutics Holdings Inc., Moderna, Inc., Lonza Group AG, Samsung Biologics Co., Ltd., TriLink BioTechnologies, Agilent Technologies, Inc., Integrated DNA Technologies, Inc., Thermo Fisher Scientific Inc., the Children's Hospital of Philadelphia, the University of Pennsylvania, the Innovative Genomics Institute and the American College of Cardiology. The brief profiles representative players in each archetype and assesses which are positioned to bring in vivo editing to approval and to common disease.

The competitive landscape is forming around six archetypes. Clinical-stage editing platform companies with pivotal and phase 3 programmes. Pharma owners and partners of in vivo editing assets. Next-generation editor developers in prime, epigenetic and novel-nuclease editing. Delivery technology providers for LNPs and tissue targeting. Manufacturers of editor mRNA, guide RNA and LNPs. Academic centres, regulators and professional bodies shaping individualized and cardiovascular pathways. Competitive intensity is rising in 2026 and is expected to sort programmes by phase 3 safety through 2029.

Where value migrates.

In 2026 value sits in pivotal and phase 3 programmes, Lilly's cardiovascular editing assets, LNP licensing and manufacturing build-out. By 2031 it moves to approved products in hereditary angioedema, alpha-1 antitrypsin deficiency and transthyretin amyloidosis, individualized therapies under the plausible mechanism pathway, cardiovascular phase 3 programmes and commercial manufacturing. By 2038 it settles in editing platform companies with approved products, pharma owners of cardiovascular editing with outcome data, delivery IP holders for liver and extrahepatic targeting, manufacturers and the centres that built editing pathways early. Programmes with unresolved safety signals and chronic therapies in refractory rare disease lose ground.

Capital is concentrated in a handful of clinical-stage platforms — Intellia, Beam, CRISPR Therapeutics and Prime — and in pharma: Lilly's acquisition of Verve, Regeneron's and Vertex's long-standing editing collaborations and Novartis's and Pfizer's delivery and platform deals, with Chinese developers advancing their own in vivo editors. Clinical output is concentrated in rare liver disease and lipid disorders, with the New England Journal of Medicine carrying the CPS1, prime editing and CTX310 reports within 15 months. Patent and research activity is concentrated in base and prime editor engineering, compact and novel nucleases, epigenetic editing, extrahepatic LNP targeting and off-target assessment. The brief tracks four indicators: phase 3 safety events, first approvals in rare liver disease, cardiovascular phase 3 starts and outcome data, and individualized therapies approved under the plausible mechanism pathway.

The United States leads on programmes, approvals, the individualized pathway and cardiovascular evidence through Intellia, Beam, CRISPR Therapeutics, Lilly, CHOP and the FDA. Europe and the United Kingdom contribute trials, conditional pathways and reimbursement precedent. China advances in vivo editors and investigator-initiated trials. Rare liver disease centres carry the first indications; cardiology the second.